Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $43.60

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $43.60.

A number of equities analysts have weighed in on the stock. Piper Sandler cut their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 target price on the stock in a research report on Friday, January 10th. Finally, HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th.

Collegium Pharmaceutical Trading Up 1.2 %

COLL stock traded up $0.34 during midday trading on Friday, hitting $29.73. The stock had a trading volume of 46,389 shares, compared to its average volume of 436,639. The company's 50-day moving average price is $30.21 and its 200 day moving average price is $32.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a market cap of $936.08 million, a PE ratio of 12.81 and a beta of 0.99. Collegium Pharmaceutical has a 12-month low of $27.28 and a 12-month high of $42.29.

Remove Ads

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. On average, equities research analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Activity

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the sale, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. This trade represents a 20.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Colleen Tupper sold 977 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now directly owns 164,269 shares in the company, valued at approximately $4,928,070. The trade was a 0.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 109,193 shares of company stock worth $3,243,594. 3.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Intech Investment Management LLC acquired a new position in Collegium Pharmaceutical in the third quarter worth about $374,000. Charles Schwab Investment Management Inc. grew its position in shares of Collegium Pharmaceutical by 4.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company's stock worth $14,741,000 after acquiring an additional 16,655 shares in the last quarter. FMR LLC increased its holdings in shares of Collegium Pharmaceutical by 1,532.2% in the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company's stock valued at $1,459,000 after acquiring an additional 35,439 shares during the last quarter. Verition Fund Management LLC raised its position in shares of Collegium Pharmaceutical by 35.1% during the 3rd quarter. Verition Fund Management LLC now owns 14,042 shares of the specialty pharmaceutical company's stock valued at $543,000 after acquiring an additional 3,652 shares in the last quarter. Finally, ClearAlpha Technologies LP bought a new position in Collegium Pharmaceutical during the third quarter worth $266,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.